Among 2 analysts covering Mistras Group (NYSE:MG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Mistras Group had 5 analyst reports since February 23, 2019 according to SRatingsIntel. Sidoti maintained Mistras Group, Inc. (NYSE:MG) rating on Tuesday, March 12. Sidoti has “Buy” rating and $21 target. Canaccord Genuity maintained Mistras Group, Inc. (NYSE:MG) rating on Thursday, March 14. Canaccord Genuity has “Hold” rating and $16.5 target. See Mistras Group, Inc. (NYSE:MG) latest ratings:

02/04/2019 Broker: BidaskScore Rating: Sell Downgrade
18/03/2019 Broker: BidaskScore Rating: Hold Upgrade
14/03/2019 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $20 New Target: $16.5 Maintain
12/03/2019 Broker: Sidoti Rating: Buy New Target: $21 Maintain
23/02/2019 Broker: BidaskScore Rating: Hold Upgrade

Sivik Global Healthcare Llc decreased Gw Phrma Plc (GWPH) stake by 81.82% reported in 2018Q4 SEC filing. Sivik Global Healthcare Llc sold 22,500 shares as Gw Phrma Plc (GWPH)’s stock rose 45.17%. The Sivik Global Healthcare Llc holds 5,000 shares with $487,000 value, down from 27,500 last quarter. Gw Phrma Plc now has $5.38B valuation. The stock decreased 3.07% or $5.55 during the last trading session, reaching $175.05. About 410,152 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 60.19% since May 19, 2018 and is uptrending. It has outperformed by 55.82% the S&P500. Some Historical GWPH News: 24/05/2018 – lsodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Cannabidiol lsolate to Sundial; 19/04/2018 – ADVISERS VOTE 13-0 GW PHARMA DRUG’S BENEFITS OUTWEIGH RISKS; 27/04/2018 – INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol ( CBD) for Treatment of Prader-Willi Syndrome; 19/04/2018 – GW PHARMA HALTED AHEAD OF TODAY’S FDA ADVISORY PANEL MEETING; 30/04/2018 – Projects will not be focusing on the cannabis plant’s psychoactive compound, known as tetrahydrocannabinol, or THC; 12/04/2018 – GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the; 19/04/2018 – GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 – SEC FILING; 24/04/2018 – Isodiol Intl Inc. Announces the Launch of 3 New Cannabidiol ( CBD) Pdt Categories With Level Brands Inc; 19/04/2018 – GW PHARMA WINS BACKING OF FDA ADVISERS FOR CANNABIS DRUG; 13/03/2018 – GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents

Among 6 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharmaceuticals had 18 analyst reports since December 3, 2018 according to SRatingsIntel. As per Tuesday, February 26, the company rating was maintained by Cowen & Co. J.P. Morgan maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Wednesday, February 27 with “Buy” rating. The firm has “Buy” rating by Piper Jaffray given on Wednesday, February 27. Oppenheimer maintained the stock with “Hold” rating in Wednesday, February 27 report. The rating was maintained by Cantor Fitzgerald on Monday, December 3 with “Overweight”. The firm earned “Overweight” rating on Tuesday, May 7 by JP Morgan. The firm earned “Buy” rating on Monday, March 18 by Cantor Fitzgerald. Cantor Fitzgerald maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Wednesday, February 27 with “Buy” rating. The firm has “Buy” rating given on Tuesday, March 5 by Piper Jaffray. The firm earned “Buy” rating on Tuesday, March 12 by Cowen & Co.

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Finance.Yahoo.com which released: “If You Had Bought GW Pharmaceuticals (NASDAQ:GWPH) Stock Five Years Ago, You Could Pocket A 171% Gain Today – Yahoo Finance” on May 16, 2019, also Nasdaq.com with their article: “Can Epidolex Drive GW Pharmaceuticals’ (GWPH) Q2 Earnings? – Nasdaq” published on May 06, 2019, Nasdaq.com published: “GW Pharmaceuticals Earnings: GWPH Stock Gains as Q1 Sales Surge 1200% – Nasdaq” on May 06, 2019. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Nasdaq.com and their article: “Has GW Pharmaceuticals (GWPH) Outpaced Other Medical Stocks This Year? – Nasdaq” published on May 10, 2019 as well as Benzinga.com‘s news article titled: “GW Pharma (NASDAQ:GWPH) – GW Pharmaceuticals Q2 Earnings Preview – Benzinga” with publication date: May 06, 2019.

Analysts await GW Pharmaceuticals plc (NASDAQ:GWPH) to report earnings on August, 6. They expect $-2.36 EPS, down 87.30% or $1.10 from last year’s $-1.26 per share. After $-1.68 actual EPS reported by GW Pharmaceuticals plc for the previous quarter, Wall Street now forecasts 40.48% negative EPS growth.

Investors sentiment decreased to 1.06 in Q4 2018. Its down 0.68, from 1.74 in 2018Q3. It dived, as 8 investors sold Mistras Group, Inc. shares while 28 reduced holdings. 14 funds opened positions while 24 raised stakes. 15.03 million shares or 1.67% less from 15.29 million shares in 2018Q3 were reported. Millennium Mngmt Ltd has invested 0% in Mistras Group, Inc. (NYSE:MG). Dimensional Fund L P reported 1.38 million shares. The Pennsylvania-based Federated Investors Pa has invested 0% in Mistras Group, Inc. (NYSE:MG). Morgan Stanley has invested 0% of its portfolio in Mistras Group, Inc. (NYSE:MG). Invesco Limited holds 0% or 37,877 shares. Cornercap Investment Counsel stated it has 53,250 shares. Rutabaga Mngmt Llc Ma holds 677,669 shares. Royal National Bank & Trust Of Canada reported 550,691 shares. Laurion Management Limited Partnership holds 27,622 shares. 331,183 were accumulated by State Street Corp. Bernzott reported 2.42% in Mistras Group, Inc. (NYSE:MG). Nj State Employees Deferred Compensation Plan owns 24,000 shares. National Serv Incorporated Wi reported 38,033 shares. Charles Schwab Invest Mngmt has 0% invested in Mistras Group, Inc. (NYSE:MG) for 92,162 shares. Ameritas Inv Prtnrs holds 0% of its portfolio in Mistras Group, Inc. (NYSE:MG) for 1,338 shares.

More notable recent Mistras Group, Inc. (NYSE:MG) news were published by: Finance.Yahoo.com which released: “MISTRAS Group Inc (MG) Q1 2019 Earnings Call Transcript – Yahoo Finance” on May 13, 2019, also Seekingalpha.com with their article: “Mistras Group’s (MG) CEO Dennis Bertolotti on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” published on May 11, 2019, Finance.Yahoo.com published: “Here’s What Hedge Funds Think About Mistras Group, Inc. (MG) – Yahoo Finance” on May 11, 2019. More interesting news about Mistras Group, Inc. (NYSE:MG) were released by: Globenewswire.com and their article: “Magna Announces 2019 Annual Meeting Results NYSE:MGA – GlobeNewswire” published on May 09, 2019 as well as Finance.Yahoo.com‘s news article titled: “Magna International, Inc. to Host Earnings Call – Yahoo Finance” with publication date: May 09, 2019.

Since December 18, 2018, it had 4 insider buys, and 0 sales for $996,946 activity. DEBENEDICTIS NICHOLAS had bought 20,000 shares worth $278,540. Shares for $207,750 were bought by Stamatakis Manuel N. on Thursday, March 14.

The stock decreased 2.62% or $0.37 during the last trading session, reaching $13.75. About 40,089 shares traded. Mistras Group, Inc. (NYSE:MG) has declined 17.72% since May 19, 2018 and is downtrending. It has underperformed by 22.09% the S&P500. Some Historical MG News: 12/03/2018 – MISTRAS GROUP INC MG.N SEES FY 2018 REVENUE $715 MLN TO $730 MLN; 12/03/2018 – MISTRAS GROUP SEES FY REV. $715M TO $730.0M, EST. $727.5M; 19/04/2018 – DJ Mistras Group Inc, Inst Holders, 1Q 2018 (MG); 12/03/2018 – MISTRAS GROUP INC – IN 2018, ADJUSTED EBITDA IS EXPECTED TO INCREASE BY 22% TO 30% OVER 2017, TO BETWEEN $78 MLN AND $83 MLN; 07/05/2018 – MISTRAS GROUP 1Q REV. $187.6M, EST. $177.7M; 12/03/2018 – Mistras 4Q Rev $187.6M; 10/04/2018 – Fenimore Asset Management Inc. Exits Position in Mistras Group; 12/03/2018 – MISTRAS GROUP 4Q ADJ EPS 15C, EST. 20C; 07/05/2018 – MISTRAS GROUP KEEPS 2018 GUIDANCE UNCHANGED; 07/05/2018 – MISTRAS GROUP INC MG.N FY2018 REV VIEW $726.4 MLN — THOMSON REUTERS l/B/E/S

Mistras Group, Inc. provides technology-enabled asset protection solutions worldwide. The company has market cap of $393.88 million. The firm operates through three divisions: Services; International; and Products and Systems. It currently has negative earnings. It offers traditional non-destructive testing, and inspection and engineering services; and designs, makes, sells, installs, and services acoustic emission sensors, instruments, and turn-key systems used for monitoring and testing materials, pressure components, processes, and structures.

Mistras Group, Inc. (NYSE:MG) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.